SCHEMBL4054486

SCHEMBL4054486

c1ccc(-c2ccc3nc(-c4ccc5ccccc5c4)oc3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.59
ESR2 Q92731 3/20 0.59
VSIR Q9H7M9 3/20 0.55
UTRN P46939 7/20 0.54
GPR119 Q8TDV5 3/20 0.51
MEN1 O00255 3/20 0.50
ALDH1A1 P00352 3/20 0.50
KMT2A Q03164 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
CYP1A2 P05177 2/20 0.50
NPC1 O15118 2/20 0.50
MAPT P10636 2/20 0.50
RAB9A P51151 2/20 0.50
KDM4E B2RXH2 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TP53 P04637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
AHR P35869 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
NOTUM Q6P988 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31319880 0.90 NPC1 (0.63) ESR1ESR2VSIRUTRNMEN1
SCHEMBL30727502 0.90 ESR1 (0.55) ESR1ESR2VSIRUTRNGPR119
SCHEMBL31319821 0.89 UTRN (0.52) ESR1ESR2VSIRUTRNMEN1
SCHEMBL31319848 0.89 UTRN (0.48) ESR1ESR2VSIRUTRNGPR119
SCHEMBL31319888 0.89 UTRN (0.52) ESR1ESR2VSIRUTRNMEN1
SCHEMBL31319853 0.89 ESR1 (0.51) ESR1ESR2VSIRUTRNGPR119
SCHEMBL29820037 0.89 GPR119 (0.61) ESR1ESR2VSIRGPR119MEN1
SCHEMBL590701 0.89 GPR119 (0.61) ESR1ESR2VSIRGPR119MEN1
SCHEMBL29819610 0.89 GPR119 (0.61) ESR1ESR2VSIRGPR119MEN1
SCHEMBL23080000 0.88 NPC1 (0.53) ESR1ESR2UTRNGPR119MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B ESR1 1649/4885ESR2 2289/4885VSIR 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.